Elżbieta Izbicka
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 12
- RNA Interference and Gene Delivery 8
- Advanced biosensing and bioanalysis techniques 8
- Epigenetics and DNA Methylation 7
- DNA and Nucleic Acid Chemistry 5
- Oncology top 5%
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 6
- Cancer Research top 5%
- Biotechnology top 5%
-
- Telomeres, Telomerase, and Senescence 6
- Co-authors
- Daniel D. Von HoffLaurence H. HurleyÉric RaymondR. A. LawrenceRichard T. WheelhouseK K DavidsonDavid NishiokaKaren Davidson
- Journals
- Journal of the American Chemical Society (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (1 paper)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Elżbieta Izbicka
96 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 119
- Molecular Biology 2.1k
- Oncology 748
- Cancer Research 332
- Pulmonary and Respiratory Medicine 421
- Biotechnology 109
Countries citing papers authored by Elżbieta Izbicka
This map shows the geographic impact of Elżbieta Izbicka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elżbieta Izbicka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elżbieta Izbicka more than expected).
Fields of papers citing papers by Elżbieta Izbicka
This network shows the impact of papers produced by Elżbieta Izbicka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elżbieta Izbicka. The network helps show where Elżbieta Izbicka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Elżbieta Izbicka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Differential activity and potential mechanism of action of pralatrexate (PDX) methotrexate, and pemetrexed (Alimta) in human cancer models in vivo and in vitro | 2007 | 1 |
| 2 | 2006 | 32 | |
| 3 | Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. | 2005 | 27 |
| 4 | 2005 | 36 | |
| 5 | 2004 | 52 | |
| 6 | 2004 | 24 | |
| 7 | 2003 | 9 | |
| 8 | 2001 | 11 | |
| 9 | 2000 | 13 | |
| 10 | 2000 | 197 | |
| 11 | 1999 | 20 | |
| 12 | 1999 | 8 | |
| 13 | 1999 | 21 | |
| 14 | 1998 | 24 | |
| 15 | 1998 | 13 | |
| 16 | 1998 | 122 | |
| 17 | 1997 | 8 | |
| 18 | 1996 | 5 | |
| 19 | 1995 | 114 | |
| 20 | 1991 | 11 |
About Elżbieta Izbicka
Elżbieta Izbicka is a scholar working on Molecular Biology, Oncology and Pharmacology, having authored 96 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (12 papers), RNA Interference and Gene Delivery (8 papers), Advanced biosensing and bioanalysis techniques (8 papers), Epigenetics and DNA Methylation (7 papers), Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (6 papers), Telomeres, Telomerase, and Senescence (6 papers) and DNA and Nucleic Acid Chemistry (5 papers). The work is most often cited by research in Molecular Biology (2.1k citations), Oncology (748 citations) and Cancer Research (332 citations). Elżbieta Izbicka has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Daniel D. Von Hoff, Laurence H. Hurley, Éric Raymond, R. A. Lawrence, Richard T. Wheelhouse, K K Davidson, David Nishioka, Karen Davidson, Gregory R. Mundy and D. Sun. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.